<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242787</url>
  </required_header>
  <id_info>
    <org_study_id>BVCL008</org_study_id>
    <nct_id>NCT01242787</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B</brief_title>
  <acronym>LB80380</acronym>
  <official_title>A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Completed LG-BVCL007 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the long-term safety and the antiviral activity of
      the optimal doses of LB80380 for additional 48 weeks in treatment-naive patients with chronic
      hepatitis B infection compared to entecavir 0.5 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LB80380, an oral prodrug, is a promising candidate nucleotide analogue with antiviral
      activity against wild-type hepatitis B virus (HBV). LB80380 is undergoing clinical
      development by LG Life Sciences for use in the treatment of chronic HBV infection.

      This study is an extension study of the Phase IIb (Protocol No. LG-BVCL007), the treatment
      period of this study is 48-week with 24-week of follow-up period
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients showing HBV DNA mutation</measure>
    <time_frame>at Week 48</time_frame>
    <description>Safety assessment including adverse events, laboratory abnormalities and DNA mutation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of HBV DNA from Baseline of LG-BVCL007 study</measure>
    <time_frame>at Week 48</time_frame>
    <description>Efficacy assessment including normalization of ALT, HBsAg seroconversion, HBeAg seroconversion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entecavir 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Entecavir 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB80380</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal dose of LB80380 (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB80380</intervention_name>
    <description>Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)</description>
    <arm_group_label>LB80380</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir 0.5 mg</intervention_name>
    <description>Entecavir 0.5 mg, by oral for 48 weeks</description>
    <arm_group_label>Entecavir 0.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who are able to participate in this expanded study without any
             interruption after completing 48 weeks treatment of LG-BVCL007 study

        Exclusion Criteria:

          -  Co-infection with hepatitis C or D virus (HCV or HDV) or HIV

          -  Decompensated liver disease

          -  ALT &gt; 10 x ULN

          -  Creatinine clearance (calculated by cockcroft-gault formula) less than 50 ml/min

          -  Alpha-fetoprotein (AFP) value greater than or equal to 50 ng/mL, and a follow-up
             ultrasonography performed prior to baseline shows findings indicative of HCC

          -  Treatment with immunomodulatory agent or corticosteroids within 6 months prior to
             study entry.

          -  Pregnancy or breast-feeding

          -  Patient is currently abusing alcohol or illicit drugs

          -  Significant systemic illnesses other than liver diseases

          -  Presence of other causes of liver disease

          -  Plan for liver transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital of Yonsei University and other 8 sites in Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008 Oct;17(10):1581-8. doi: 10.1517/13543784.17.10.1581 . Review.</citation>
    <PMID>18808318</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, Lai CL. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrob Agents Chemother. 2009 May;53(5):1779-85. doi: 10.1128/AAC.01290-08. Epub 2009 Feb 17.</citation>
    <PMID>19223649</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology. 2010 Mar;51(3):767-76. doi: 10.1002/hep.23462.</citation>
    <PMID>20091678</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11(8):977-83.</citation>
    <PMID>17302367</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2010</study_first_posted>
  <last_update_submitted>April 13, 2012</last_update_submitted>
  <last_update_submitted_qc>April 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>LB80380</keyword>
  <keyword>treatment-naive</keyword>
  <keyword>entecavir</keyword>
  <keyword>Extension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

